<?xml version="1.0" encoding="UTF-8"?>
<p>Sensitive and specific diagnostic methods are always preferred, especially in the cases of epidemics or pandemics, for the rapid and accurate diagnosis of viruses. Molecular (RT-PCR) assays are fast, highly sensitive, and specific, and are gradually replacing conventional methods. According to data maintained by the Foundation for Innovative New Diagnostics (FIND), one of the WHOâ€™s partners for the assessment of diagnostics, at least 143 COVID-19 molecular diagnostic kits are in commercial use worldwide [
 <xref rid="B110-pathogens-09-00519" ref-type="bibr">110</xref>]. Among these, 22 kits have already been assigned for emergency use authorization (EUA) by the U.S. Food and Drug Administration (FDA). The details of the selected kits are provided in 
 <xref rid="pathogens-09-00519-t004" ref-type="table">Table 4</xref>.
</p>
